Cytek Biosciences, Inc. Q3 FY2024 earnings call

Key Points

• Wenbin Jiang emphasized solid growth despite soft market conditions, citing flow cytometry as an essential tool vs discretionary tech. Key pillars: instruments, applications, bioinformatics, clinical. Bioinformatics user base over 13,600. Clinical products approved in China and EU.
• Bill McCombe discussed financials: Total revenue up 10% QoQ to $51.5M, GAAP gross profit $29M, adjusted EBITDA $7.6M. Share repurchases of $12.1M in Q3, with $277.8M in cash and marketable securities.

Total revenue for the third quarter was $51.5 million, a 7% year-over-year growth. Product revenue (primarily instruments) increased 3% year-over-year, driven by international markets. Service revenue grew 25% year-over-year. Geographically, EMEA and APAC had double-digit revenue growth, and the US showed sequential improvement, especially in the biopharma sector. Adjusted EBITDA was positive at $7.6 million. Revenue breakdown: Total revenue $51.5M, with product revenue and service revenue contributing, and geographic growth in EMEA, APAC, and US recovery in biopharma.

Guidance

• Reaffirmed full-year 2024 revenue guidance: $203M to $210M (5-9% growth Y-o-Y). Expect GAAP net loss in single digits and positive cash flow from operations. Fourth quarter expected to have a sequential step-up, leveraging normal seasonal patterns and essential nature of products.

Q: Elaboration on US demand vs discretionary spend A: Flow cytometry is essential for daily lab needs unlike discretionary tech, differentiating Cytek from peers.

Q: Fourth quarter guidance assumptions A: Normal seasonal pattern, with essential spend supporting the sequential step-up in Q4.

Q: 2025 guidance A: No 2025 revenue guidance yet, but EBITDA expected to grow with revenue growth and cost control.

Q: APAC strength and China A: APAC includes multiple regions, China impact seen but expected to normalize next year.

Q: 4Q visibility A: Order book depends on last few weeks of the quarter as most orders come in the final weeks.

Q: Clinical pathway in US A: Working on 510(k) process and LDT applications with reputable labs in the US.

Q: Service attachment rates A: Tied to installed base growth and instrument usage frequency, tracking installed base growth long-term.

Q: Instrument replacement cycle A: Customers extending instrument life but moving to advanced tech, with harmonization across labs driving demand for Cytek's technology